BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare ...

-- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% placebo-adjusted BMI reduction in patients (N=120) with acquired hypothalamic obesity -- -- U.S. and EU regulatory ...

(MENAFN- GlobeNewsWire - Nasdaq) -- Second quarter 2025 net product revenue from global sales of IMCIVREE ® (setmelanotide) of $48.5 million -- -- U.S. and EU regulatory submissions for setmelanotide ...